WallStreetZenWallStreetZen

NASDAQ: ARQT
Arcutis Biotherapeutics Inc Stock Forecast, Predictions & Price Target

OverviewForecast
EarningsDividendOwnership

Analyst price target for ARQT

Based on 6 analysts offering 12 month price targets for Arcutis Biotherapeutics Inc.
Min Forecast
$24.00+192.68%
Avg Forecast
$41.50+406.1%
Max Forecast
$57.00+595.12%

Should I buy or sell ARQT stock?

Based on 6 analysts offering ratings for Arcutis Biotherapeutics Inc.
Strong Buy
Strong Buy
5 analysts 83.33%
Buy
1 analysts 16.67%
Hold
0 analysts 0%
Sell
0 analysts 0%
Strong Sell
0 analysts 0%

Be the first to know when Wall Street analysts revise their ARQT stock forecasts and price targets.

ARQT stock forecasts by analyst

Analyst / FirmRatingActionPrice TargetUpside/DownsideDateAnalyst Color
Truist Securities
Top 31%
70
Strong BuyMaintains$40.00+387.80%2023-05-26
Needham
Bottom 8%
8
BuyReiterates$24.00+192.68%2023-05-17
Goldman Sachs
Bottom 33%
33
Strong BuyMaintains$33.00+302.44%2023-05-11
Morgan Stanley
Bottom 16%
16
Strong BuyMaintains$45.00+448.78%2023-05-10
Mizuho
Bottom 7%
7
Strong BuyMaintains$57.00+595.12%2023-05-10
Morgan Stanley
Bottom 10%
10
Strong BuyMaintains$50.00+509.76%2023-03-01

1 of 1

Forecast return on equity

Is ARQT forecast to generate an efficient return?
Company
N/A
Industry
0.1%
Market
71.95%

Forecast return on assets

Is ARQT forecast to generate an efficient return on assets?
Company
N/A
Industry
0.12%

ARQT revenue growth forecast

How is ARQT forecast to perform vs Biotechnology companies and vs the US market?
Company
317.77%
Industry
39.96%
Market
8.44%
ARQT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Industry Forecast
ARQT's revenues are forecast to... subscribe to Premium to read more.
Forecast Revenue Growth vs Market Forecast

ARQT vs Biotech Stocks

TickerPricePrice TargetUp/downsideConsensus
ARQT$8.20$41.50+406.10%Strong Buy
ALPN$10.53$14.00+32.95%Strong Buy
AUTL$2.90$8.25+184.48%Strong Buy
PHAT$11.66$24.67+111.55%Buy
TNYA$7.64$18.00+135.60%Strong Buy
View Top Biotech Stocks

Arcutis Biotherapeutics Stock Forecast FAQ

Is Arcutis Biotherapeutics Stock a good buy in 2023, according to Wall Street analysts?

The consensus among 6 Wall Street analysts covering (NASDAQ: ARQT) stock is to Strong Buy ARQT stock.

Out of 6 analysts, 5 (83.33%) are recommending ARQT as a Strong Buy, 1 (16.67%) are recommending ARQT as a Buy, 0 (0%) are recommending ARQT as a Hold, 0 (0%) are recommending ARQT as a Sell, and 0 (0%) are recommending ARQT as a Strong Sell.

If you're new to stock investing, here's how to buy Arcutis Biotherapeutics stock.

What is ARQT's forecast return on equity (ROE) for 2023-2026?

(NASDAQ: ARQT) forecast ROE is N/A, which is considered weak.

What is ARQT's Price Target?

According to 6 Wall Street analysts that have issued a 1 year ARQT price target, the average ARQT price target is $41.50, with the highest ARQT stock price forecast at $57.00 and the lowest ARQT stock price forecast at $24.00.

On average, Wall Street analysts predict that Arcutis Biotherapeutics's share price could reach $41.50 by May 26, 2024. The average Arcutis Biotherapeutics stock price prediction forecasts a potential upside of 406.1% from the current ARQT share price of $8.20.

What is ARQT's forecast return on assets (ROA) for 2023-2026?

(NASDAQ: ARQT) forecast ROA is N/A, which is lower than the forecast US Biotechnology industry average of 0.12%.
©2023 WallStreetZen
Company
AboutBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsHelp GuidesContactTwitterYouTube
Stock Tools
Top Performing AnalystsStock ScreenerStock ForecastTrending StocksStrong Buy StocksHighest Earnings StocksBest Dividend Paying StocksStatisticsStock Market SectorsStock Market IndustriesHow to Buy Stocks Online
Stock Ideas
Buy The DipBiggest Stock Gainers TodayBiggest Stock Losers Today52 Week High Stocks52 Week Low StocksMost Active Stocks TodayMost Undervalued StocksBest Penny Stocks to Buy NowBest Stocks Under $5Best Stocks Under $10
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.